Unassociated Document
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending October 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 
GlaxoSmithKline plc
                     
Notification of Transactions of Directors, Persons Discharging
Managerial Responsibilities or Connected Persons
 
In accordance with DTR 3.1.4R(1)(a) I give details of changes in the notional interests of the following Directors and Persons Discharging Managerial Responsibilities ('PDMR'), who acquired Ordinary Shares and American Depositary Shares (ADSs), at a price of 1268.00 pence per Ordinary Share and $38.74 per ADS, following the re-investment of dividends paid on Ordinary Shares and ADSs held in the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
 
 
 
Director/PDMR
 
Number of Ordinary Shares acquired under the personal contribution element of the plan
 
Number of Ordinary Shares acquired under the matching element of the plan
(GSK contribution)
 
Sir Andrew Witty
 
1,923.720
 
1,923.720
 
Mr S Dingemans
 
734.152
 
734.152
 
Mr R G Connor
 
383.401
 
383.401
 
Mr N Hirons
 
83.072
 
83.072
 
Mr S A Hussain
 
329.008
 
329.008
 
Mr D S Redfern
 
410.867
 
410.867
 
Ms C Thomas 
 
281.943
 
281.943
 
Mr P C Thomson
 
138.574
 
138.574
 
Dr P J T Vallance
 
984.208
 
984.208
 
Ms E Walmsley
 
580.548
 
580.548
 
 
 
Director/PDMR
 
Number of ADSs acquired under the personal contribution element of the plan
 
Number of ADSs acquired  under the matching element of the plan
(GSK contribution)
 
Dr M M Slaoui
 
740.389
 
740.389
 
Mr D E Troy
 
313.282
 
313.282
 
GlaxoSmithKline plc ('GSK') was advised of these allocations on 19 October 2015.
 
V A Whyte
Company Secretary
 
20 October 2015
 
 
                                                                                                                                                                            SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: October 20, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc